Chris Moreau
Chief Executive Officer chez ALGERNON PHARMACEUTICALS INC.
Fortune : 82 123 $ au 31/03/2024
Profil
Christopher Joseph Moreau is currently the Chief Executive Officer & Director at Algernon Pharmaceuticals, Inc. He previously held positions as the President, CEO, Director & Head-Investor Relations at Luminor Medical Technologies, Inc. from 2011 to 2015.
He also served as the Chief Executive Officer at Nash Pharmaceuticals, Inc. Additionally, he was a Director at First Responder Technologies, Inc. from 2019 to 2020.
He has also held the position of President at Advansis Capital Corp.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/02/2024 | 1 001 502 ( 5,00% ) | 82 123 $ | 31/03/2024 |
Postes actifs de Chris Moreau
| Sociétés | Poste | Début |
|---|---|---|
| ALGERNON PHARMACEUTICALS INC. | Chief Executive Officer | 01/03/2018 |
Anciens postes connus de Chris Moreau
| Sociétés | Poste | Fin |
|---|---|---|
| QUEBEC PEGMATITE HOLDINGS CORP. | President | 24/07/2019 |
Luminor Medical Technologies, Inc.
 Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Luminor Medical Technologies, Inc. engages in acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. It develops technology programs: Scout DS Diabetes Screen, PreVu Skin Cholesterol Test for fiabetes, and coronary artery disease. The company was founded on June 27, 1998 and is headquartered in Toronto, Canada. | Chief Executive Officer | 21/04/2016 |
Nash Pharmaceuticals, Inc.
 Nash Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nash Pharmaceuticals, Inc. engages in the research and development of repurposed therapeutic drugs and pharmaceutical products. Its focus areas include non-alcoholic steatohepatitis, chronic kidney disease, and inflammatory bowel disease. The company is headquartered in Vancouver, Canada. | Chief Executive Officer | - |
| Advansis Capital Corp. | President | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALGERNON PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Luminor Medical Technologies, Inc.
Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Luminor Medical Technologies, Inc. engages in acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. It develops technology programs: Scout DS Diabetes Screen, PreVu Skin Cholesterol Test for fiabetes, and coronary artery disease. The company was founded on June 27, 1998 and is headquartered in Toronto, Canada. | Commercial Services |
| Advansis Capital Corp. | |
First Responder Technologies, Inc.
 First Responder Technologies, Inc. Aerospace & DefenseElectronic Technology First Responder Technologies, Inc. is in the process of exploring business opportunities. The company was founded on January 27, 2017 and is headquartered in Vancouver, Canada. | Electronic Technology |
Nash Pharmaceuticals, Inc.
Nash Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nash Pharmaceuticals, Inc. engages in the research and development of repurposed therapeutic drugs and pharmaceutical products. Its focus areas include non-alcoholic steatohepatitis, chronic kidney disease, and inflammatory bowel disease. The company is headquartered in Vancouver, Canada. | Health Technology |
